A
Adam J. Devall
Researcher at University of Birmingham
Publications - 55
Citations - 1463
Adam J. Devall is an academic researcher from University of Birmingham. The author has contributed to research in topics: Miscarriage & Pregnancy. The author has an hindex of 16, co-authored 41 publications receiving 683 citations. Previous affiliations of Adam J. Devall include Children's of Alabama & City Hospitals Sunderland NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss
Siobhan Quenby,Siobhan Quenby,Ioannis D. Gallos,Rima K Dhillon-Smith,Marcelina Podesek,Mary D. Stephenson,Joanne D. Fisher,Jan J. Brosens,Jan J. Brosens,Jane Brewin,Rosanna Ramhorst,Emma S. Lucas,Emma S. Lucas,Rajiv C. McCoy,Robert Anderson,Shahd Daher,Lesley Regan,Maya Al-Memar,Tom Bourne,David A. MacIntyre,Raj Rai,Ole Bjarne Christiansen,Mayumi Sugiura-Ogasawara,Joshua Odendaal,Joshua Odendaal,Adam J. Devall,Phillip R. Bennett,Stavros Petrou,Arri Coomarasamy +28 more
TL;DR: In the UK, the pooled risk of miscarriage is 15·3% (95% CI 12·5-18·7%) of all recognized pregnancies, and three or more miscarriages is 0·7% (0·5 −0·8%) as discussed by the authors.
Journal ArticleDOI
Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
Fiona S. Togneri,Douglas G. Ward,Joseph M. Foster,Adam J. Devall,Paula Wojtowicz,Sofia Alyas,Fabiana Ramos Vasques,Assa Oumie,Nicholas D. James,Kar Keung Cheng,Maurice P. Zeegers,Nayneeta Deshmukh,Brendan O'Sullivan,Philippe Taniere,Karen G. Spink,Dominic J. McMullan,Mike Griffiths,Richard T. Bryan +17 more
TL;DR: In this article, the authors compared the genomic profiles of urinary cellular DNA and cell-free DNA (cfDNA) from the urine with matched diagnostic formalin-fixed paraffin-embedded tumour DNAs for 23 well-characterised UBC patients.
Journal ArticleDOI
A randomized trial of progesterone in women with bleeding in early pregnancy
Arri Coomarasamy,Adam J. Devall,Versha Cheed,Hoda Harb,Lee J Middleton,Ioannis D. Gallos,Helen Williams,Abey Eapen,Tracy E Roberts,Chriscasimir C. Ogwulu,Ilias Goranitis,Jane P Daniels,A. Ahmed,Ruth Bender-Atik,Kalsang Bhatia,Cecilia Bottomley,Jane Brewin,Meenakshi Choudhary,Fiona Crosfill,Shilpa Deb,W Colin Duncan,Andrew K Ewer,Kim Hinshaw,T. Holland,Feras Izzat,Jemma Johns,Kathiuska Kriedt,Mary Ann Lumsden,Padma Manda,Jane E. Norman,Natalie Nunes,Caroline E. Overton,Siobhan Quenby,Sandhya Rao,Jackie Ross,A. Shahid,Martyn Underwood,Nirmala Vaithilingam,Linda Watkins,Catherine Wykes,Andrew W Horne,Davor Jurkovic +41 more
TL;DR: Progesterone therapy administered during the first trimester did not result in a significantly higher incidence of live births than placebo and the incidence of adverse events did not differ significantly between the groups.
Journal ArticleDOI
Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Wei Shen Tan,Wei Shen Tan,Anesh Panchal,Laura Buckley,Adam J. Devall,Laurence Loubiere,Ann Pope,Mark R. Feneley,Jo Cresswell,R. Issa,Hugh Mostafid,Sanjeev Madaan,Rupesh Bhatt,John S. McGrath,Vijay Sangar,T.R. Leyshon Griffiths,Toby Page,Dominic Hodgson,S.N. Datta,Lucinda Billingham,John D. Kelly,John D. Kelly +21 more
TL;DR: This study did not show a difference in bladder cancer outcomes between microwave-heated chemotherapy and standard of care treatment, and suggested RITE may be a second-line therapy for non-CIS recurrence following BCG failure.
Journal ArticleDOI
Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence
Arri Coomarasamy,Adam J. Devall,Jan J. Brosens,Siobhan Quenby,Mary D. Stephenson,Sony Sierra,Ole Bjarne Christiansen,Rachel Small,Jane Brewin,Tracy E Roberts,Rima K Dhillon-Smith,Hoda Harb,Hannah Noordali,Argyro Papadopoulou,Abey Eapen,Matthew Prior,Gian Carlo Di Renzo,Kim Hinshaw,Ben W.J. Mol,Mary Ann Lumsden,Yacoub Khalaf,Andrew Shennan,Mariëtte Goddijn,Madelon van Wely,Maya Al-Memar,Phil Bennett,Tom Bourne,Raj Rai,Lesley Regan,Ioannis D. Gallos +29 more
TL;DR: Women with a history of miscarriage who present with bleeding in early pregnancy may benefit from the use of vaginal micronized progesterone 400 mg twice daily, and women and their care providers should use the findings for shared decision-making.